Loading...
Anti-platelet therapy: glycoprotein IIb-IIIa antagonists
Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. Three agents are approved for clinical use. In this review, the characteristics of each agent, their pharmacodynamic profile, results in pivotal clinical trials and the associated clinical implications are discuss...
Saved in:
| Main Author: | |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Blackwell Science Inc
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3195742/ https://ncbi.nlm.nih.gov/pubmed/21906121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03879.x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|